GMAB:NSD-Genmab A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.52

Change

+1.22 (+4.16)%

Market Cap

USD 19.59B

Volume

0.83M

Average Target Price

USD 29.00 (-4.98%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Genmab A/S, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM) indications; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL) indications. Its products under development include Ofatumumab to treat multiple sclerosis; Tisotumab vedotin for treating cervical and ovarian cancers, and solid tumors; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of thyroid eye disease; Camidanlumab tesirine (ADCT-301) to treat Hodgkin lymphoma and solid tumors; HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat acute myeloid leukemia (AML); JNJ-64007957 and JNJ-64407564 for MM; JNJ-63898081 to treat solid tumors; JNJ-67571244 to treat AML or myelodysplastic syndrome; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked antibodies, bispecific antibodies, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. It also has a research collaboration and license agreement with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and CureVac AG for the research and development of differentiated mRNA-based antibody products. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-18.46 (-6.48%)

USD73.88B 49.39 37.03
REGN Regeneron Pharmaceuticals, Inc

-24.70 (-4.33%)

USD64.13B 28.64 21.76
SGEN Seattle Genetics, Inc

-4.04 (-2.59%)

USD26.26B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.30 (+1.28%)

USD22.70B 9.81 8.43
INCY Incyte Corporation

-0.69 (-0.69%)

USD21.60B 47.64 35.20
MRNA Moderna, Inc

-11.29 (-16.36%)

USD21.42B N/A N/A
BMRN BioMarin Pharmaceutical Inc

+6.23 (+6.39%)

USD17.63B 154.78 92.86
ALNY Alnylam Pharmaceuticals, Inc

-4.09 (-2.91%)

USD16.13B N/A N/A
GLPG Galapagos NV

+4.45 (+2.22%)

USD13.13B 70.13 37.04
BGNE BeiGene, Ltd

+4.78 (+3.00%)

USD12.41B N/A N/A

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap
EL4C:XETRA Deka STOXX Europe Strong .. 6.18 % 0.67 %

+0.35 (+0.78%)

USD0.11B
EL4C:F Deka STOXX Europe Strong .. 6.18 % 0.67 %

+0.46 (+1.03%)

USD0.11B
IDNA iShares Genomics Immunolo.. 4.04 % 0.47 %

-1.24 (-3.35%)

USD0.06B
EL4E:XETRA Deka STOXX Europe Strong .. 3.50 % 0.65 %

+0.45 (+1.69%)

USD0.02B
EL4E:F Deka STOXX Europe Strong .. 3.50 % 0.65 %

+0.53 (+2.00%)

USD0.02B
MEU:CA Mackenzie Maximum Diversi.. 1.65 % 0.61 %

+0.36 (+1.75%)

USD0.02B
DWCR Arrow DWA Country Rotatio.. 0.00 % 0.95 %

+0.57 (+2.45%)

USD7.99M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.68% 74% C 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.68% 74% C 89% B+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 19.59B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 52.40 16% F 20% F
Price/Book Ratio 8.75 21% F 13% F
Price / Cash Flow Ratio 14.78 5% F 19% F
EV/EBITDA 5.57 33% F 77% C+
Management Effectiveness  
Return on Equity 20.98% 97% A+ 90% A-
Return on Invested Capital 17.63% 93% A 91% A-
Return on Assets 14.22% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.41 70% C- 67% D+
Short Percent N/A N/A N/A N/A N/A
Beta 0.42 87% B+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.